Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 80,291 |
|
|||||
| News | - | ||||||
| Day High | 4.74 | Low High |
|||||
| Day Low | 4.58 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Savara Inc | SVRA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.125 | 2.73% | 4.705 | 09:40:42 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.68 | 4.58 | 4.74 | 4.58 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 736 | 80,291 | US$ 4.70 | US$ 377,556 | - | 1.83 - 5.70 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 09:47:37 | 3 | US$ 4.71 | USD |
Savara Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 646.53M | 138.15M | - | 0 | -54.7M | -0.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Savara News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SVRA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.66 | 4.74 | 4.06 | 4.43 | 759,970 | 0.045 | 0.97% |
| 1 Month | 4.65 | 5.34 | 4.06 | 4.86 | 919,013 | 0.055 | 1.18% |
| 3 Months | 4.76 | 5.70 | 4.06 | 4.96 | 859,905 | -0.055 | -1.16% |
| 6 Months | 3.64 | 5.70 | 3.115 | 4.62 | 857,102 | 1.07 | 29.26% |
| 1 Year | 1.87 | 5.70 | 1.83 | 4.09 | 689,735 | 2.84 | 151.60% |
| 3 Years | 1.87 | 5.70 | 1.02 | 2.88 | 443,443 | 2.84 | 151.60% |
| 5 Years | 10.80 | 11.96 | 0.69 | 2.68 | 689,718 | -6.10 | -56.44% |
Savara Description
| Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
